Triple therapy aims to turn inoperable bowel cancer into a surgical target
NCT ID NCT07446465
First seen Mar 24, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This study tests whether combining chemotherapy (FOLFOX), a targeted drug (fruquintinib), and an immunotherapy (serplulimab) can shrink advanced colorectal cancer enough to allow surgery. About 42 adults with a specific type of colorectal cancer (pMMR/MSS) that cannot be removed initially will receive the combination as their first treatment. The main goals are to see how many tumors become operable and how many shrink significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (LOCALLY ADVANCED OR METASTATIC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Xuhui, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.